title: An eye on the future of inflammasomes and drug development in AMD.
abstract: Age-related macular degeneration (AMD) is the leading cause of central vision loss worldwide. While activation of the immune system has been implicated in disease progression, the pathways involved remain relatively unclear. Typically, inflammatory responses are caused as a result of pathogenic infection. However, in chronic conditions, like AMD, a form of 'sterile' inflammation can exist in localised areas of the body in response to modified host-derived elements and particulate matter accumulation, due to the activation of a complex termed the 'inflammasome'. Inflammasomes control the activity of two major pro-inflammatory cytokines, namely, interleukin (IL)-1β and IL-18, by allowing for their cleavage from inactive pro-forms into mature cytokines. The major pathological hallmark common to both 'dry' and 'wet' AMD is the presence of extracellular deposits, known as drusen, below the retinal pigment epithelium in the macula of the eye. Past studies have shown that host-derived particulate matter such as amyloid deposits and atherosclerotic plaques can be 'sensed' by the NLRP3-inflammasome causing cleavage of pro-IL-1β and pro-IL-18. We have recently reported that the NLRP3-inflammasome can also 'sense' drusen isolated from human AMD donor eyes and that IL-18 protects against the development of choroidal neovascularisation in a model that mimics 'wet' AMD. In fact, since then, a number of studies have reported roles for the NLRP3-inflammasome in AMD. This review will focus on describing, comparing and contrasting these reports and analyzing the potential for manipulating the NLRP3-inflammasome as a therapy for AMD.
authors: Ocular Genetics Unit, Trinity College Dublin, Lincoln Place Gate, Dublin 2, Ireland. matthew.campbell@tcd.ie
authors: Matthew
authors: M
authors: Campbell
authors: Sarah L
authors: SL
authors: Doyle
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000276:immunology; D055808:Drug Discovery; D006801:Humans; D058847:Inflammasomes; D007249:Inflammation; D008268:Macular Degeneration / Q000276:immunology*; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein
chemical_list: D002352:Carrier Proteins; D058847:Inflammasomes; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C453881:NLRP3 protein, human
references: Immunol Lett. 2012 Sep;147(1-2):29-33
references: 22698681
references: Nature. 2008 Jul 24;454(7203):428-35
references: 18650913
references: Front Immunol. 2012 Sep 21;3:296
references: 23049533
references: Nat Med. 2011 Feb;17(2):179-88
references: 21217695
references: Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15324-9
references: 21876127
references: Nature. 2011 Jan 13;469(7329):221-5
references: 21124315
references: Nat Med. 2012 May;18(5):791-8
references: 22484808
references: Annu Rev Genomics Hum Genet. 2009;10:19-43
references: 19405847
references: Hum Mol Genet. 2005 Jun 1;14(11):1449-55
references: 15829498
references: Nat Immunol. 2010 Oct;11(10):897-904
references: 20835230
references: Am J Clin Nutr. 2006 Feb;83(2):447S-455S
references: 16470011
references: Am J Pathol. 2011 May;178(5):2416-23
references: 21514452
references: Arch Ophthalmol. 1990 Oct;108(10):1442-7
references: 1699513
references: Nat Immunol. 2008 Aug;9(8):847-56
references: 18604214
references: Int Rev Immunol. 2011 Feb;30(1):16-34
references: 21235323
references: Science. 2005 Apr 15;308(5720):385-9
references: 15761122
references: Arch Ophthalmol. 2006 Jul;124(7):995-1001
references: 16832023
references: Immunol Rev. 2008 Jun;223:20-38
references: 18613828
references: Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1652-9
references: 18385087
references: Nature. 2006 Mar 9;440(7081):237-41
references: 16407889
references: Cell. 2010 Mar 19;140(6):821-32
references: 20303873
references: N Engl J Med. 2008 Oct 2;359(14):1456-63
references: 18753640
references: Rejuvenation Res. 2005 Spring;8(1):3-5
references: 15798367
references: Arch Ophthalmol. 1994 Jun;112(6):813-8
references: 7516148
references: Crit Rev Biochem Mol Biol. 2012 Sep;47(5):424-43
references: 22681257
references: Prog Retin Eye Res. 2009 Sep;28(5):348-68
references: 19560552
references: J Am Board Fam Pract. 2002 Mar-Apr;15(2):142-52
references: 12002198
references: Nat Rev Immunol. 2007 May;7(5):353-64
references: 17457343
references: PLoS One. 2008;3(11):e3554
references: 18978936
references: Nature. 2002 Dec 19-26;420(6917):846-52
references: 12490957
references: Nature. 2013 Jan 31;493(7434):674-8
references: 23254930
references: Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14682-7
references: 12391305
references: J Biol Chem. 2012 Oct 19;287(43):36617-22
references: 22948162
references: Science. 2008 Aug 1;321(5889):691-6
references: 18669862
references: Trends Mol Med. 2011 May;17(5):276-82
references: 21376667
references: Cell. 2012 May 11;149(4):847-59
references: 22541070
references: Nature. 2006 Mar 9;440(7081):228-32
references: 16407890
references: Nat Immunol. 2011 May;12(5):408-15
references: 21478880
references: Mitochondrion. 2010 Aug;10(5):411-8
references: 20573557
references: Nat Immunol. 2010 May;11(5):373-84
references: 20404851
references: Nat Immunol. 2008 Aug;9(8):857-65
references: 18604209
references: Annu Rev Immunol. 2002;20:197-216
references: 11861602
references: Annu Rev Immunol. 2010;28:321-42
references: 20307211
references: Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):109-16
references: 16898079
references: Acta Ophthalmol. 2012 Jun;90(4):299-309
references: 22112056
references: N Engl J Med. 2009 May 21;360(21):2252-4; author reply 2255-6
references: 19469038
references: J Immunol. 2011 Oct 15;187(8):4374-83
references: 21930971
references: Nat Immunol. 2010 Feb;11(2):136-40
references: 20023662
references: J Biol Chem. 2003 Oct 24;278(43):42027-35
references: 12923198
references: Invest Ophthalmol Vis Sci. 2013 Jan 07;54(1):110-20
references: 23221073
references: Nature. 2010 Apr 29;464(7293):1357-61
references: 20428172
references: Nature. 2010 Oct 21;467(7318):972-6
references: 20927103
references: Nat Immunol. 2012 May 18;13(6):535-42
references: 22610250
references: Immunity. 2012 Mar 23;36(3):401-14
references: 22342844
references: J Pathol. 2013 Jan;229(2):141-4
references: 23097196
references: J Pathol. 2007 Jan;211(2):144-56
references: 17200946
references: Exp Eye Res. 2010 Mar;90(3):465-71
references: 20059996
references: Nat Rev Drug Discov. 2012 Aug;11(8):633-52
references: 22850787
references: Rejuvenation Res. 2011 Dec;14(6):651-60
references: 22007913
references: Cytokine Growth Factor Rev. 2003 Oct;14(5):361-8
references: 12948519
references: Science. 2010 Jan 15;327(5963):296-300
references: 20075245
references: N Engl J Med. 2005 Apr 21;352(16):1685-95
references: 15843671
references: Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5614-8
references: 19628747
references: Nature. 2011 Mar 17;471(7338):325-30
references: 21297615
references: Trends Cell Biol. 2009 Sep;19(9):455-64
references: 19716304
references: Arch Ophthalmol. 2009 Apr;127(4):533-40
references: 19365036
references: Nat Immunol. 2010 May;11(5):404-10
references: 20383149
references: Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):983-8
references: 12483320
references: Nature. 2012 Dec 6;492(7427):123-7
references: 23143333
references: Gerontology. 1995;41 Suppl 2:15-28
references: 8821318
references: Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20388-93
references: 19918053
references: Trends Pharmacol Sci. 2012 Oct;33(10):542-51
references: 22944460
references: Adv Immunol. 2006;91:159-73
references: 16938540
references: J Ophthalmol. 2012;2012:319728
references: 22174998